Please login to the form below

Not currently logged in
Email:
Password:

Kite Pharma

This page shows the latest Kite Pharma news and features for those working in and with pharma, biotech and healthcare.

Latest news

  • Gilead swoops on Forty Seven with $4.9bn all-cash deal Gilead swoops on Forty Seven with $4.9bn all-cash deal

    a run of M&A that hit a peak in 2017 with Gilead’s $11.9bn acquisition of CAR-T cell therapy player Kite Pharma. ... Magrolimab complements our existing work in haematology, adding a non-cell therapy programme that complements Kite’s pipeline of cell

  • Gilead owes BMS millions after losing Yescarta patent infringement trial Gilead owes BMS millions after losing Yescarta patent infringement trial

    The basis of the lawsuit is that Yescarta, which is marketed by Gilead’s Kite Pharma division, infringed on a patent licensed by BMS’ Juno Therapeutics from Sloan Kettering and the ... It alleged that Kite scientists copied research from the

  • Gilead promotes Andrew Dickinson to CFO, increased M&A expected Gilead promotes Andrew Dickinson to CFO, increased M&A expected

    Dickinson helmed company’s acquisition of Kite and partnership with Galapagos. Andrew Dickinson has been selected as Gilead's new chief financial officer – as the pharma giant looks to expand outside ... During his time at Gilead, Dickinson oversaw

  • Gilead unveils plan to separate Kite cell therapy unit Gilead unveils plan to separate Kite cell therapy unit

    Comes as Yescarta misses analyst expectations. Gilead's new CEO Daniel O’Day has lost no time in putting his seal on the company, announcing plans to separate its Kite cell ... for Kite, which will be operating in a highly competitive field and needs

  • Riva leaves Gilead to head Glenmark’s innovation spin-off Riva leaves Gilead to head Glenmark’s innovation spin-off

    Company has own bispecific antibody platform. Indian pharma company Glenmark has appointed Alessandro Riva as the chief executive of its new spin-off company focused on innovative medicines. ... He played a lead role in acquiring CAR-T pioneers Kite

More from news
Approximately 15 fully matching, plus 36 partially matching documents found.

Latest Intelligence

  • The good, the bad and the ugly The good, the bad and the ugly

    The company hopes its $12bn acquisition of Kite Pharma (August 2017) will help it steal a march on the lucrative CAR-T market through its treatment for advanced lymphoma. ... The data this article was based on is available in full online:

  • Pharma deals continue to slide Pharma deals continue to slide

    Given big pharma’s reluctance to spend on M&A it is perhaps surprising that this month Gilead has announced the $11.9bn acquisition of Kite Pharma. ... Licensing  . The most common licensing deal is big pharma licensing in from biotech.

  • Deal Watch January 2017 Deal Watch January 2017

    Kite Pharma. Daiichi Sankyo. Licence. Cellular cancer therapy axicabtagene ciloleucel (KTE-C19). ... 160. Kite Pharma. Fosun Pharma. Formation of a JV. Autologous T-cell therapies in cancer.

  • Deal Watch November 2016 Deal Watch November 2016

    As Juno wrestles with bad publicity and a depressed share price, Novartis and Kite Pharma, also active in the CAR T cell space, presented promising data at the ASH meeting for ... licence. 115.5. Medivir | BioPhausia/ Karo Pharma. business with 13

  • Deal Watch June 2016 Deal Watch June 2016

    licence. 770. Teva and Allergan/ Mayne Pharma. US generic portfolio of 37 approved and 5 FDA filed products. ... licence. 80. Cell Design Labs/ Kite Pharma. 'On/off switch' technology to regulate activity of engineered CAR T-cells for AML, certain B-cell

More from intelligence
Approximately 0 fully matching, plus 8 partially matching documents found.

Latest appointments

More from appointments
Approximately 4 fully matching, plus 6 partially matching documents found.

Latest from PMHub

  • Understanding the evolving CAR-T market

    Big pharma also wanted a slice of the action. Aggressive deal-making quickly became central to the rise of CAR-T, with Gilead acquiring Kite Pharma for a mammoth $11.9bn ... So, what does pharma need to do to avoid being overtaken by the competition and

  • How do you define a biotech company?

    Johnson &Johnson and Pfizer are two of the largest pharma companies in the world by revenue but both have numerous biological therapies. ... This approach is particularly apparent in some of the recent examples of technology pioneered by biotech

More from PMHub
Approximately 0 fully matching, plus 2 partially matching documents found.

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
3 Monkeys Zeno

3 Monkeys Zeno is an award winning global creative communications consultancy – home to a collective of creative and strategic...

Latest intelligence

InSite Mapping™ - a Novel Tool for Insight-gathering and Patient Journey Mapping
Learn how a client engaged 18 rheumatologist advisors over 6 months to create a patient journey map for SLE....
Alone we can do so little, together we can do so much
Collaboration is at the heart of successful patient engagement and effective healthcare provision. But in such a complex, nuanced network, true collaborations are rare. So how can we, as an...
7 important considerations for creating an inclusive clinical trial website
You might have noticed that all of us here at COUCH Health are big advocates for taking action to improve diversity and inclusion in the world of clinical research. ‘Taking...

Infographics